Physician profile
Frank E Masci
NPI 1689645871
$3,759.21
in general payments reported to CMS, 2019-2025
17 companies · $1,776 in 2025
The $1,776 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $103 · 2021: $217 · 2022: $524 · 2023: $602 · 2024: $250 · 2025: $1,776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,628.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $973.55 | 2025 | M22 |
| Sun Pharmaceutical Industries INC. | $554.37 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $359.08 | 2019-2023 | |
| Alcon Vision LLC | $342.95 | 2022-2025 | Rocklatan, Rhopressa, Eysuvis |
| Allergan, INC. | $294.73 | 2019-2022 | |
| Oyster Point Pharma, INC. | $284.31 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $211.44 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $182.91 | 2023-2025 | Xiidra, Miebo |
| Dompe US, INC. | $115.43 | 2023-2025 | Oxervate |
| Glaukos Corporation | $114.93 | 2019 | |
| Glaxosmithkline, LLC. | $95.66 | 2022 | |
| Aerie Pharmaceuticals, INC. | $76.77 | 2019-2021 | |
| Abbvie INC. | $76.37 | 2022-2023 | |
| Thea Pharma INC. | $23.77 | 2025 | Iyuzeh |
| Shire North American Group INC | $21.39 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $15.91 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Masci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.